<DOC>
	<DOCNO>NCT00077025</DOCNO>
	<brief_summary>This study carry see treatment ZD1839 ( Gefitinib ) combine Arimidex ( Anastrozole ) improve efficacy Arimidex alone prevent progression metastatic breast cancer .</brief_summary>
	<brief_title>Comparing Anastrozole-Placebo Combination Anastrozole-ZD1839 Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer</brief_title>
	<detailed_description>This phase II , multicenter , double-blind , randomize , placebo-controlled trial . Patients randomize double-blind manner 1:1 ratio receive either 250 mg/day ZD1839 match placebo combination 1 mg/day anastrozole . The dose ZD1839 select base clinical study tumor type suggest identical efficacy together well toxicity profile patient treat 250 mg compare 500 mg/day . The 1 mg dose anastrozole standard approve dose .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Female postmenopausal patient age 18 year old newly diagnose metastatic breast cancer . Patients recurrent disease adjuvant tamoxifen patient hormone therapy na√Øve eligible trial . A paraffin embed tumor tissue block slide either metastatic primary tumor site require . Patients hormone replacement therapy study . Prior chemotherapy receive metastatic disease allow . Previous treatment tyrosine kinase inhibitor aromatase inhibitor allow . Patients evidence active interstitial lung disease eligible .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>metastatic breast cancer</keyword>
</DOC>